SK bioscience Co.,Ltd.

KRX:302440.KS

55500 (KRW) • At close September 13, 2024
Overview | Financials

Numbers are in millions (except for per share data and ratios) KRW.

2024 Q22024 Q12023 Q42023 Q32023 Q22023 Q12022 Q42022 Q32022 Q22022 Q12021 Q42021 Q32021 Q22021 Q12020 Q42020 Q32020 Q22020 Q12019 Q42019 Q32019 Q22019 Q12018 Q42018 Q3
Revenue 26,777.43422,270.67890,604.217231,826.28426,478.22720,596.828140,300.83191,052.875138,280.83287,091.333450,857.868220,828.833144,604.268112,709.96167,008.97698,689.07639,420.93722,661.91255,595.34250,472.96651,158.52526,710.86940,304.9547,868.638
Cost of Revenue 10,389.50418,560.53662,920.483126,344.48719,997.49519,711.70791,521.74635,264.07352,135.30639,283.159168,368.00289,476.20361,566.07139,307.52736,292.95946,994.91530,836.28516,144.55834,898.24829,022.38720,181.80121,975.56922,770.89226,187.177
Gross Profit 16,387.933,710.14227,683.734105,481.7976,480.732885.12148,779.08555,788.80286,145.52647,808.174282,489.866131,352.6383,038.19773,402.43430,716.01751,694.1618,584.6536,517.35420,697.09521,450.57930,976.7234,735.317,534.05821,681.461
Gross Profit Ratio 0.6120.1670.3060.4550.2450.0430.3480.6130.6230.5490.6270.5950.5740.6510.4580.5240.2180.2880.3720.4250.6060.1770.4350.453
Reseach & Development Expenses 29,806.7624,473.2421,122.35924,879.74926,246.03916,139.69324,332.52817,441.75311,074.95812,319.0814,784.87315,623.9337,690.3659,150.9049,925.8086,508.41204,543.7438,165.915,445.33405,560.3797,137.4423,374.969
General & Administrative Expenses 1,417.05533,498.2352,012.19944,544.4321,660.26930,073.92701,497.5821,303.551,097.9651,225.4961,125.3321,120.406696.129818.578472.96211,675.256572.263621.513546.69614,283.125603.782580.086543.113
Selling & Marketing Expenses 4,047.197-19,149.0146,133.5764,866.3434,189.8333,193.14405,538.034,032.2553,124.7073,885.9572,839.5332,518.8812,327.3554,124.0182,318.03101,830.3123,441.6332,878.35302,357.93,462.332,451.871
SG&A 14,151.67814,349.22117,198.09344,544.4325,850.10230,073.92722,805.8217,035.6125,335.8054,222.6725,111.4533,964.8653,639.2873,023.4844,942.5962,790.99311,675.2562,402.5754,063.1463,425.04914,283.1252,961.6824,042.4162,994.984
Other Expenses -502.217-188.659-435.018-89,088.864-796.997-16,139.693-136.2599,952.6248,545.0927,514.4391,275.839859.6371,741.43916.119647.9012,222.298686.768-476.363-406.559-2.57244.83153.238-532.87552.069
Operating Expenses 44,460.65539,011.1238,755.47-44,544.43241,789.74330,073.92747,274.60834,429.98924,955.85524,056.19128,546.05630,946.39916,883.60219,687.21319,804.24615,220.58411,675.25610,931.53615,691.36312,482.98314,283.12512,605.70513,731.32510,277.537
Operating Income -28,072.725-35,300.978-11,071.73660,937.365-35,309.011-29,188.8071,504.47740,490.28461,189.67123,751.983253,943.811100,406.23166,154.59453,715.22110,911.77236,473.577-3,090.603-4,414.1825,005.7328,967.59616,693.598-7,870.4073,802.73411,403.924
Operating Income Ratio -1.048-1.585-0.1220.263-1.334-1.4170.0110.4450.4430.2730.5630.4550.4570.4770.1630.37-0.078-0.1950.090.1780.326-0.2950.0940.238
Total Other Income Expenses Net 11,171.64115,495.36714,676.655-2,314.7156,074.113,523.36728,952.657-17,314.27-5,846.6199,005-766.445-3,833.8231,737.0571,326.884-283.4631,531.718-240.675-1,424.773-2,095.564-575.979-693.495-946.21-13,521.382-821.285
Income Before Tax -16,901.084-19,805.6113,604.91858,622.65-29,234.901-25,665.4430,457.13323,176.01455,343.05232,756.983251,622.01696,572.40867,891.65255,042.10410,628.30838,005.295-3,331.279-5,838.9552,910.1688,391.61716,000.103-8,816.615-9,718.64910,582.639
Income Before Tax Ratio -0.631-0.8890.040.253-1.104-1.2460.2170.2550.40.3760.5580.4370.4690.4880.1590.385-0.085-0.2580.0520.1660.313-0.33-0.2410.221
Income Tax Expense -5,492.189-6,087.616-564.69210,230.689-13,258.905-11,397.5842,715.572,397.8859,217.114,950.66867,656.48520,135.10715,079.87313,117.439750.0245,797.481-803.605-815.191-841.4463,163.4892,048.485-562.661-2,256.7572,699.903
Net Income -11,408.895-13,717.9954,169.61148,391.961-15,975.996-14,267.85627,741.56320,778.12946,125.94227,806.315183,965.53176,437.30152,811.7841,924.6659,878.28432,207.814-2,527.673-5,023.7643,751.6135,228.12813,951.618-8,253.955-7,461.8917,882.736
Net Income Ratio -0.426-0.6160.0460.209-0.603-0.6930.1980.2280.3340.3190.4080.3460.3650.3720.1470.326-0.064-0.2220.0670.1040.273-0.309-0.1850.165
EPS -148.5-178.5654.3630.23-208.06-185.82361.292716013632,447.671,0176936591,614.19526-40.74-82.491,839.164756,839-4,046-3,730.63,941
EPS Diluted -148.5-178.1254.14630.23-208.06-185.26360.19270598361.042,447.671,0106886541,614.19526-40.74-82.491,839.164756,839-4,046-3,730.63,941
EBITDA -18,998.346-26,171.791-1,975.351105,481.797-20,468.507885.1219,353.1747,637.18281,308.58933,482.554261,844.035105,534.69472,489.10257,774.62420,104.08444,297.2721,016.413-3,997.97810,212.74810,459.51120,314.762-5,065.0965,973.53412,314.685
EBITDA Ratio -0.709-1.175-0.0220.455-0.7730.0430.0670.5230.5880.3840.5810.4780.5010.5130.30.4490.026-0.1760.1840.2070.397-0.190.1480.257